Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMJEVITA vs DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
Rheumatoid arthritis (moderate to severe active, alone or with methotrexate),Juvenile idiopathic arthritis (moderate to active polyarticular, age ≥2 years),Psoriatic arthritis (active, alone or with DMARDs),Ankylosing spondylitis (active),Crohn's disease (moderate to severe, age ≥6 years),Ulcerative colitis (moderate to severe, adults),Plaque psoriasis (moderate to severe chronic, adults),Hidradenitis suppurativa (moderate to severe, adults),Uveitis (non-infectious intermediate, posterior, and panuveitis, adults and children ≥2 years)
treatment of symptomatic benign prostatic hyperplasia (BPH),combination therapy for BPH
Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
Terminal elimination half-life is approximately 14 days (range 10-20 days) in patients receiving 40 mg every other week. This long half-life supports biweekly dosing.
Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours).
Adalimumab is a monoclonal antibody; it is not metabolized by cytochrome P450 enzymes. Clearance occurs via catabolism to small peptides and amino acids.
Dutasteride is extensively metabolized by CYP3A4 and CYP3A5; tamsulosin is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4.
Adalimumab (AMJEVITA) is eliminated primarily via intracellular catabolism, with negligible renal or biliary excretion. No intact drug is excreted in urine. The Fe receptor-mediated recycling contributes to long half-life.
Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces.
Adalimumab is a monoclonal antibody; protein binding is negligible as it is not bound to serum proteins. However, it may bind to soluble TNF-alpha with high affinity.
Dutasteride: >99.5% bound to albumin and alpha-1-acid glycoprotein. Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein.
Volume of distribution (Vd) is approximately 4.7-6.0 L (0.06-0.08 L/kg for a 70 kg adult). This small Vd reflects distribution primarily in the vascular and interstitial spaces, consistent with a large protein.
Dutasteride: Vd 300-500 L (total body, large tissue distribution). Tamsulosin: Vd 0.2 L/kg (approx 14-30 L, moderate distribution).
Subcutaneous bioavailability: 64% (range 50-80%) after 40 mg SC injection. No intravenous formulation is approved; absolute bioavailability determined by comparison to IV administration.
Dutasteride: Oral bioavailability ~60% (enhanced with food). Tamsulosin: Oral bioavailability ~30% (increased with food; formulation designed for consistent absorption).
No dose adjustment required for any degree of renal impairment.
No dosage adjustment is required for renal impairment. Tamsulosin is extensively metabolized and renally excreted as inactive metabolites; however, no specific GFR-based adjustments are recommended.
No dose adjustment required for any degree of hepatic impairment.
Dutasteride is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For mild to moderate hepatic impairment (Child-Pugh A or B), no dosage adjustment is recommended, but caution is advised.
For pediatric patients weighing ≥40 kg: 40 mg subcutaneously every other week; for weight <40 kg: 20 mg subcutaneously every other week.
Safety and efficacy in pediatric patients have not been established. Use is not recommended in patients under 18 years of age.
No specific dose adjustment recommended; use with caution due to higher risk of infections.
No specific dose adjustment is required based on age alone. Elderly patients may be more sensitive to orthostatic hypotension from tamsulosin; monitor blood pressure and advise caution when rising from a seated or lying position.
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), invasive fungal infections, and other opportunistic pathogens. Patients should be tested for latent TB before and during therapy. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
None
Serious infections (bacterial, viral, fungal, including reactivation of HBV),Invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, candidiasis),Malignancies (lymphoma, leukemia, melanoma, Merkel cell carcinoma, other),Anaphylaxis and allergic reactions,Demyelinating disease (new onset or exacerbation of CNS demyelinating disorders),Hematologic reactions (pancytopenia, aplastic anemia),Congestive heart failure (new onset or worsening),Lupus-like syndrome (autoantibodies, rarely clinical disease),Hepatitis B reactivation,Use with abatacept or anakinra (increased risk of infection)
Orthostatic hypotension/syncope, especially with concurrent antihypertensives,Intraoperative floppy iris syndrome during cataract surgery,Risk of high-grade prostate cancer (increased Gleason score 8-10 with dutasteride),Hepatic impairment may increase exposure,Sexual dysfunction: decreased libido, erectile dysfunction, ejaculation disorders
Known hypersensitivity to adalimumab or any component of the formulation,Active serious infection including sepsis
Hypersensitivity to dutasteride, tamsulosin, or other 5α-reductase inhibitors,Women who are or may become pregnant (risk of fetal harm due to androgen inhibition),Severe hepatic impairment (Child-Pugh Class C),History of orthostatic hypotension
No specific food interactions. No dietary restrictions required.
Absorption of tamsulosin is decreased when taken with food; however, the combination product should be taken 30 minutes after a meal to maintain consistent exposure. Avoid grapefruit juice as it may increase tamsulosin concentrations. No specific food interactions with dutasteride.
Amjevita (adalimumab) is an Ig G1 monoclonal antibody that crosses the placenta during the third trimester, with highest fetal exposure in the third trimester. In the first and second trimesters, placental transfer is limited. Available data from the OTIS autoimmune diseases in pregnancy study and other cohort studies do not indicate a substantially increased risk of major birth defects or miscarriage with adalimumab exposure during pregnancy. However, there is a potential risk of immunosuppression in the neonate, including increased risk of infections, if the mother is exposed during the second and third trimesters. Infants should not be vaccinated with live vaccines for at least 5 months after maternal last dose.
Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosin has no known teratogenic risk. First trimester: Dutasteride exposure may cause feminization of male fetuses. Second and third trimesters: Risk persists; avoid use.
Adalimumab is excreted in breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.04. Limited data indicate that infants are exposed to less than 1% of the maternal dose, and no adverse effects have been reported in breastfed infants. Because adalimumab is a large protein, it undergoes proteolysis in the infant's gastrointestinal tract and is not systemically absorbed. Therefore, breastfeeding is considered compatible with adalimumab therapy.
Unknown if dutasteride or tamsulosin are excreted in human milk. Dutasteride is lipophilic and may appear in milk. Tamsulosin likely excreted. M/P ratio not available. Due to potential for adverse effects (e.g., hypotension), breastfeeding is not recommended during therapy.
During pregnancy, adalimumab clearance may increase, especially in the third trimester, leading to lower trough concentrations. However, no dose adjustment is routinely recommended due to lack of data showing altered clinical outcomes. Therapeutic drug monitoring is not standard, but if disease activity increases, consider modifying the dose or frequency as per non-pregnant guidelines. Postpartum, clearance returns to prepregnancy levels, so doses should be adjusted back to prepregnancy regimen if modified.
No dose adjustment studies in pregnancy. Dutasteride should not be used; tamsulosin is not recommended. No pharmacokinetic changes requiring dose adjustment are established, but avoid use.
AMJEVITA (adalimumab-atto) is a biosimilar to Humira. Administer subcutaneously; rotate injection sites. Do not administer live vaccines. Screen for TB and hepatitis B before initiation. Consider withholding for serious infections. Monitor for allergic reactions and blood dyscrasias.
Dutasteride/tamsulosin is a fixed-dose combination for benign prostatic hyperplasia (BPH). Dutasteride is a 5α-reductase inhibitor that reduces prostate volume over months; tamsulosin is an α1-adrenoceptor antagonist providing rapid symptom relief. Do not split or crush capsules. Avoid use in women and children. Monitor for orthostatic hypotension, especially when initiating therapy. Assess for drug-drug interactions: CYP3A4 inhibitors (e.g., ketoconazole) increase dutasteride exposure; tamsulosin interacts with other α-blockers, antihypertensives, and PDE5 inhibitors. Counsel patients about risk of postural hypotension and syncope. Advise patients to avoid driving or hazardous activities until they know how the medication affects them. Dutasteride may cause sexual dysfunction (decreased libido, ejaculatory dysfunction, gynecomastia). Tamsulosin may cause intraoperative floppy iris syndrome during cataract surgery; inform ophthalmologist of use. Monitor serum PSA levels: dutasteride decreases PSA by ~50% after 6 months; establish new baseline. Do not use in patients with history of prostate cancer.
Store in refrigerator, do not freeze; protect from light.,Inject at room temperature; allow to sit out 15-30 minutes.,Rotate injection sites; avoid tender, bruised, or scarred skin.,Report signs of infection (fever, chills, cough) or allergic reaction immediately.,Do not receive live vaccines while on this medication.,Inform all healthcare providers of your use of AMJEVITA.
Take this medication once daily, 30 minutes after the same meal each day.,Swallow capsules whole; do not crush, chew, or open.,Rise slowly from sitting or lying down to avoid dizziness or fainting.,Avoid driving or operating machinery until you know how the drug affects you.,Inform your doctor if you plan to have cataract surgery, as this drug may cause complications.,Do not donate blood while taking this medication, as it may harm a fetus if given to a pregnant woman.,Women who are pregnant or may become pregnant should not handle crushed or broken capsules.,Report any breast lumps, pain, or nipple discharge, as gynecomastia is possible.,Use condoms if your partner is pregnant, as dutasteride can be absorbed through skin contact with semen.,Keep all appointments for PSA blood tests; the test result will be lower than expected.,Do not take other alpha-blocker medications for blood pressure or prostate problems while on this drug unless prescribed.,Grapefruit juice may increase side effects; limit or avoid consumption.,Do not stop taking this medication suddenly without consulting your doctor.
No interactions on record
"Tamsulosin, an alpha-1 adrenergic antagonist, and fosinopril, an ACE inhibitor, both lower blood pressure through distinct mechanisms, leading to additive hypotensive effects. This synergistic action increases the risk of orthostatic hypotension, dizziness, syncope, and falls, particularly at treatment initiation or dose escalation. The interaction is of clinical concern in elderly patients or those with volume depletion."
"Lofexidine, a central alpha-2 adrenergic agonist, reduces sympathetic outflow and can cause bradycardia and hypotension. Tamsulosin, an alpha-1 adrenergic receptor antagonist, also lowers blood pressure, especially orthostatic. Combined use leads to additive hypotensive effects, increasing risk of symptomatic bradycardia, orthostatic hypotension, syncope, and falls, particularly at therapy initiation or dose titration."
"The combination of tamsulosin and moexipril can lead to an increased risk of hypotension and orthostatic hypotension due to additive vasodilatory effects. Tamsulosin, an alpha-1 adrenergic antagonist, reduces peripheral vascular resistance, while moexipril, an ACE inhibitor, decreases angiotensin II production, further promoting vasodilation. This synergistic effect may cause symptomatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or during dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMJEVITA vs DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, answered by our medical review team.
AMJEVITA is a TNF-alpha Inhibitor that works by Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMJEVITA and DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMJEVITA is: Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.. The standard adult dose of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is: One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMJEVITA and DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMJEVITA is classified as Category C. Amjevita (adalimumab) is an IgG1 monoclonal antibody that crosses the placenta during the third trimester, with highest fetal exposure in the third trimester. In the first and seco. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is classified as Category A/B. Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.